(Press-News.org) CHICAGO, IL (May 29, 2013)—Researchers from Fox Chase Cancer Center and other institutions have completed a phase II clinical trial that may help identify those patients with HPV-positive oropharyngeal cancer who do not require the full radiation dose given in a standard regimen of Intensity-Modulated Radiation Therapy (IMRT). Preliminary findings will be presented by Shanthi Marur, first author on the study and an oncologist at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, at the 49th Annual Meeting of the American Society of Clinical Oncology on Sunday, June 2.
Patients enrolled in the trial received an initial regimen of chemotherapy followed by treatment with the targeted therapy cetuximab, a monoclonal antibody. In the study, a patient's response to those initial treatments determined the dose during radiation treatment.
"Those patients who had a really good response to chemotherapy might also be more responsive to radiation," says Barbara Burtness, senior author on the study and chief of head and neck medical oncology at Fox Chase. "Therefore, the use of a full dose of radiation for those patients might represent overtreatment."
Burtness is also chair of the Eastern Cooperative Oncology Group (ECOG), which sponsors this ongoing trial. ECOG is a a National Cancer Institute-funded team of researchers who organize and carry out clinical trials.
According to the National Cancer Institute, more than 40,000 people will be diagnosed with cancer of the oropharynx—a swath of tissue at the back of the throat—in 2013, and nearly 8,000 will die from the disease. Between 60 and 80 percent of cases are associated with infection by Human Papilloma Viruses, or HPVs.
"Patients with HPV-associated oropharyngeal cancer tend to be younger than other oropharyngeal cancer patients, and would be living with the aftereffects of treatment for more years," says Burtness. A patient who undergoes standard radiation to the back of the throat—usually between 66 and 70 Gy—may suffer serious side effects like dry mouth and disfunction in swallowing.
The investigators suspected a subset of HPV-associated oropharyngeal cancer patients, identified by their response to chemotherapy, may be suitable for trials of lower radiation.
Burtness and her co-investigators enrolled 90 patients in the trial, 80 of whom were analyzable. Of those patients, 95 percent were men, and the median age was 57. The researchers reported that most patients tolerated the induction chemotherapy and treatment with cetuximab, and 96 percent completed all three cycles. Forty-six patients had a complete clinical response, which meant all signs of the primary tumor had disappeared following treatment. These patients went on to receive a lower-than-standard dose of radiation, at 54 Gy.
The researchers report that most patients tolerated the treatment with low incidence of high-grade side effects, but other data are premature. The primary endpoint of the study is two-year progression-free survival, the fraction of patients whose diseases have not worsened after two years. The investigators say that if the two-year progression-free survival rate is at least 85 percent, further studies on lower-dose radiation are warranted.
"We do not expect that anyone would want to lower the dose of radiation based on this study, which is very much a developmental study," says Burtness. "We've never had a comparative trial of low dose versus standard dose IMRT."
Burtness notes among patients who received a lower dose of radiation, "what seemed to predict for a slightly worse outcome was either a heavy smoking history (more than 10 pack years), or those with larger tumors."
She says that although it's too early to draw definitive conclusions, the early results "may justify further study of deintensifying radiation among nonsmokers with HPV-associated oropharyngeal cancers."
###
In addition to Burtness and Marur, other investigators include Christine H. Chung at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD; David R. Trevarthen at the Swedish Medical Center in Denver; Shuli Li at the Dana-Farber Cancer Institute in Boston, MA; Weiqiang J. Zhao and Maura Gillison at the Ohio State University College of Medicine in Columbus, OH; Alexander D. Colevas at the Stanford Cancer Center in Stanford, Calif.; Anthony J. Cmelak at the Vanderbilt-Ingram Cancer Center in Nashville, TN; Julie E. Bauman at the University of Pittsburgh Medical Center, PA; Lynne I. Wagner at Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, IL; Balkrishna N. Jahagirdar at HealthPartners and Regions Cancer Care Center in St. Paul, MN; William H. Westra at the Johns Hopkins Hospital in Baltimore, MD; Robert Ferris at the University of Pittsburgh Cancer Institute, PA. The study is sponsored by ECOG.
Fox Chase Cancer Center, part of Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase also was among the first institutions to receive the National Cancer Institute's prestigious comprehensive cancer center designation in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are routinely recognized in national rankings, and the Center's nursing program has achieved Magnet status for excellence three consecutive times. Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research and oversees programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX-CHASE (1-888-369-2427) or visit http://www.foxchase.org. END
Researchers investigate a less toxic radiation treatment for HPV-Positive oropharynx cancer
2013-05-31
ELSE PRESS RELEASES FROM THIS DATE:
New therapy is tolerable in lung cancer
2013-05-31
CHICAGO, IL (May 28, 2013)—A promising new therapy for the most common form of lung cancer appears to produce largely manageable side effects, and an ongoing clinical trial is determining whether the compound treats tumors more effectively than what's on the market, according research that scientists at Fox Chase Cancer Center will present at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1.
"We're very excited about this drug," says Hossein Borghaei, DO, chief of thoracic medical oncology at Fox Chase. "I think if we learn how ...
Many solid tumors carry genetic changes targeted by existing compounds
2013-05-31
CHICAGO, IL (May 28, 2013)—Nearly two-thirds of solid tumors carry at least one mutation that may be targeted, or medicated, by an existing compound, according to new findings from researchers Fox Chase Cancer Center that will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology on June 3. The results suggest that it may one day become commonplace for doctors to sequence tumors before deciding on a treatment regimen.
"Extended sequencing of a patient's tumor is not something that's routinely done now," says study author Patrick Boland, ...
Bright light therapy may improve sleep and promote recovery in patients with mild TBI
2013-05-31
DARIEN, IL – A new study suggests that bright light therapy may improve sleep, cognition, emotion and brain function following mild traumatic brain injury (TBI).
Results show that six weeks of morning bright light therapy resulted in a marked decrease in subjective daytime sleepiness. This improvement was further associated with improvements in the propensity to fall asleep and nighttime sleep quality. Bright light therapy also affected depressive symptoms.
"Our preliminary data suggests that morning bright light therapy might be helpful to reduce subjective daytime ...
No need to battle with cattle
2013-05-31
A new study by the Wildlife Conservation Society's Animal & Human Health for the Environment And Development (AHEAD) Program, World Wildlife Fund (WWF), and regional partners finds that a new approach to beef production in southern Africa could positively transform livelihoods for farmers and pastoralists, while helping to secure a future for wildlife and wildlife-based tourism opportunities.
Market access for livestock and livestock products from Africa is constrained by the presence of foot and mouth disease (FMD). Fear of the FMD virus largely precludes large-scale ...
UCLA-led team may have found key to cause of Cushing disease
2013-05-31
FINDINGS:
Cushing disease is a life-threatening disorder most commonly triggered by tumors, often benign, in the pituitary glands, resulting in excess production of adrenocorticotrophic hormone (ACTH). The condition is marked by progressive weight gain, excessive fatty tissue deposits and a rounding of facial features, known as "moon face," and can lead to diabetes, hypertension, osteoporosis, obesity and psychological disturbances.
Cushing disease, which is more common in women than men, is also associated with a three- to four-fold increase ...
Elevated carbon dioxide making arid regions greener
2013-05-31
WASHINGTON—Scientists have long suspected that a flourishing of green foliage around the globe, observed since the early 1980s in satellite data, springs at least in part from the increasing concentration of carbon dioxide in Earth's atmosphere. Now, a study of arid regions around the globe finds that a carbon dioxide "fertilization effect" has, indeed, caused a gradual greening from 1982 to 2010.
Focusing on the southwestern corner of North America, Australia's outback, the Middle East, and some parts of Africa, Randall Donohue of the Commonwealth Scientific and Industrial ...
For first time atomic changes in a molecule during a chemical reaction photographed
2013-05-31
Taking an image of an individual molecule while it undergoes a chemical reaction has been deemed one of the holy grails of chemistry. Scientists at the University of Berkeley and the University of the Basque Country (UPV-EHU) have managed, for the very first time, to take direct, single-bond-resolved images of individual molecules just before and immediately after a complex organic reaction. The images enable appreciating the processes of the rupture and creation of links between the atoms making up a molecule. The article, entitled Direct Imaging of Covalent Bond Structure ...
The scoop on bird poop
2013-05-31
Gastrointestinal bacteria are important for digestion, immune functions and general health. Wouter van Dongen and colleagues from the Konrad Lorenz Institute of Ethology of the Vetmeduni Vienna have collaborated with scientists from the Laboratoire Évolution & Diversité Biologique (EDB), Toulouse and from the US Geological Survey, Anchorage to study the cloacal bacterial assemblies of black-legged kittiwakes (Rissa tridactyla). The bacteria in the cloaca are known to be similar to assemblages deeper within the gastrointestinal tract, so the researchers examined samples ...
Live and let die
2013-05-31
This news release is available in German.
A protein called c-FLIP-R is critical to immune cell survival: If this molecule is missing, the cells kill themselves – and are thus no longer able to perform their job fighting off invaders. Now, scientists at the Helmholtz Centre for Infection Research (HZI) Braunschweig and at the Otto von Guericke University (OvGU) Magdeburg have published their findings in the renowned European Journal of Immunology.
Apoptosis, programmed cell death, is a kind of cellular suicide program. If something triggers it, the cells perish ...
Magnetic monopoles erase data
2013-05-31
This news release is available in German. A physical particle postulated 80 years ago could provide a decisive step toward the realization of novel, highly efficient data storage devices. Scientists at the Technische Universitaet Muenchen (TUM), the Technische Universitaet Dresden and the University of Cologne found that with magnetic monopoles in magnetic vortices, called skyrmions, information can be written and erased.
Iron filings strewn on a sheet of paper trace the field lines of a bar magnet below the paper, thereby showing the magnet's north and south poles. ...